Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors-Reference-Cited by-同舟云学术

Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors

Published:2024-02-28 Issue:4 Volume:27 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Kubeczko Marcin¹,Tudrej Patrycja²,Tyszkiewicz Tomasz²,Krzywon Aleksandra³,Oczko‑Wojciechowska Małgorzata²,Jarząb Michał¹

Affiliation:

1. Breast Cancer Center, Maria Sklodowska‑Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Upper Silesia 44‑102, Poland

2. Department of Clinical and Molecular Genetics, Maria Sklodowska‑Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Upper Silesia 44‑102, Poland

3. Department of Biostatistics and Bioinformatics, Maria Sklodowska‑Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Upper Silesia 44‑102, Poland

Publisher

Spandidos Publications

Reference67 articles.

1. Current and future burden of breast cancer: Global statistics for 2020 and 2040;Arnold;Breast,2022

2. Erratum to ‘Major advancements in metastatic breast cancer treatment: When expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409];Miglietta;ESMO Open,2022

3. CDK4/6 inhibitors: Mechanisms of resistance and potential biomarkers of responsiveness in breast cancer;Cetin;Future Oncol,2022

4. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: A review of subgroup analyses from the MONALEESA-2 trial;Hortobagyi;Breast Cancer Res,2018

5. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009